{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:07:22Z","timestamp":1790888842055,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>To date, immune checkpoint inhibitors (ICIs) have emerged as a leading treatment for metastatic cancer, significantly improving patient survival while causing relatively few side effects. However, the objective response rate for ICIs remains low approximately 30% in urothelial carcinoma (UC), underscoring the urgent need for predictive response biomarkers. Several state-of-the-art signatures have been revealed in top-tier journals, highlighting the importance of this field. As the number of genes (~20,000) far exceeds the sample sizes of typical training sets (generally \u2264 300), we first developed feature selection procedures to reduce the number of features to a few hundred. We then trained multiple machine learning classifiers using the selected genes and the IMvigor210 dataset, which includes RNA-seq and clinical data from ~298 patients with metastatic UC (mUC). Notably, our predictor LogitDA, using the identified 49-gene signature, achieved a prediction AUC of 0.75 in an independent dataset, PCD4989g(mUC). Moreover, our signature outperformed six state-of-the-art signatures, PD-L1 IHC, and five tumor microenvironment signatures, including IFN-\u03b3, T-effector, and T-cell exhaustion signatures. When we integrated each of the six known signatures with our own, our signature still surpassed the integrated ones in terms of prediction AUC and accuracy in the PCD4989g(mUC) dataset. From our signature, we identified key prognostic biomarkers, with the top five markers LYRM1, RFC4, CENPL, SPAG5, and CACYBP (Benjamini-Hochberg adjusted P &amp;lt; 0.0025) in the IMvigor210 dataset. Finally, we performed pathway analyses using Reactome (MSigDB) and KEGG, to reveal some immune-related pathways enriched such as MHC class II antigen presentation.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1607222","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:17:41Z","timestamp":1763619461000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Gene signature for response prediction to immunotherapy and prognostic markers in metastatic urothelial carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Peter","family":"Langfelder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En-Tni","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ta","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Lung","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace S.","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0686-0","article-title":"A model combining clinical and genomic factors to predict response to PD-1\/PD-L1 blockade in advanced urothelial carcinoma","volume":"122","author":"Nassar","year":"2020","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","article-title":"Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072532","article-title":"Immunotherapy in renal cell carcinoma: the future is now","volume":"21","author":"Deleuze","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1038\/s41467-021-24112-w","article-title":"Molecular determinants of response to PD-L1 blockade across tumor types","volume":"12","author":"Banchereau","year":"2021","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1038\/s41467-022-31535-6","article-title":"Network-based machine learning approach to predict immunotherapy response in cancer patients","volume":"13","author":"Kong","year":"2022","journal-title":"Nat Commun"},{"key":"B9","article-title":"Unsupervised domain adaptation by backpropagation","author":"Ganin","year":"2015"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz372","article-title":"PRECISE: a domain adaptation approach to transfer predictors of drug response from pre-clinical models to tumors","volume":"35","author":"Mourragui","year":"2019","journal-title":"Bioinformatics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1217414","article-title":"Feature selection translates drug response predictors from cell lines to patients","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0687-1","article-title":"Evolutionary dynamics of neoantigens in growing tumors","volume":"52","author":"Lakatos","year":"2020","journal-title":"Nat Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.082","article-title":"RECIST 1.1\u2013Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12064-012-0162-3","article-title":"Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples","volume":"131","author":"Wagner","year":"2012","journal-title":"Theory Biosci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13059-014-0550-8","article-title":"Differential analysis of count data\u2013the DESeq2 package","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1198\/016214502753479248","article-title":"Comparison of discrimination methods for the classification of tumors using gene expression data","volume":"97","author":"Dudoit","year":"2002","journal-title":"J Am Stat Assoc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00524","article-title":"Detecting prognosis risk biomarkers for colon cancer through multi-omics-based prognostic analysis and target regulation simulation modeling","volume":"11","author":"Yin","year":"2020","journal-title":"Front Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04082-1","article-title":"B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity","volume":"599","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-021-00820-9","article-title":"Cancer-cell-derived GABA promotes \u03b2-catenin-mediated tumour growth and immunosuppression","volume":"24","author":"Huang","year":"2022","journal-title":"Nat Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.710286","article-title":"CXCL9 is a potential biomarker of immune infiltration associated with favorable prognosis in ER-negative breast cancer","volume":"11","author":"Liang","year":"2021","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12894-023-01258-x","article-title":"NUF2 is correlated with a poor prognosis and immune infiltration in clear cell renal cell carcinoma","volume":"23","author":"Zheng","year":"2023","journal-title":"BMC Urol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-019-0950-7","article-title":"A six-gene prognostic model predicts overall survival in bladder cancer patients","volume":"19","author":"Wang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2013a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B32","first-page":"3960","article-title":"The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response","volume":"15","author":"Wang","year":"2023","journal-title":"Am J Trans Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.3390\/ijms21113949","article-title":"NF-\u03baB and its role in checkpoint control","volume":"21","author":"Betzler","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.779175","article-title":"Cell division cycle-associated genes are potential immune regulators in nasopharyngeal carcinoma","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B36","unstructured":"Gene signature for response prediction to immunotherapy in mUC and RCC\n          \n          \n            \n              Langfelder\n              P\n            \n            \n              Lin\n              E-T\n            \n            \n              Tsai\n              Y-T\n            \n            \n              Cha\n              T-L\n            \n            \n              Shieh\n              GS\n            \n          \n          (Tech Rep No 2025-02) Institute of Statistical Science, Academia Sinica, Taipei, Taiwan.\n          \n          2025"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1430583","article-title":"Development and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer","volume":"15","author":"Shen","year":"2025","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"589711","DOI":"10.1038\/s41467-025-56462-0","article-title":"Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohorts","volume":"16","author":"Boll","year":"2024","journal-title":"bioRxiv"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e70175","DOI":"10.1002\/ctm2.70175","article-title":"Immune profiling of the macroenvironment in colorectal cancer unveils systemic dysfunction and plasticity of immune cells","volume":"15","author":"Ke","year":"2025","journal-title":"Clin Trans Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"114579","DOI":"10.1016\/j.intimp.2025.114579","article-title":"NCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90\u03b1\/EZH2\/CXCL9 axis in colon cancer","volume":"155","author":"Liu","year":"2025","journal-title":"Int\u00a0Immunopharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/s12885-025-14246-1","article-title":"Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e009358","DOI":"10.1136\/jitc-2024-009358","article-title":"Impact of LAG-3\/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma","volume":"12","author":"Yoshida","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41467-022-33980-9","article-title":"Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer","volume":"13","author":"Damrauer","year":"2022","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/JCO.22.00205","article-title":"Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: a multicenter, randomized, phase II trial (BAYOU)","volume":"41","author":"Rosenberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00262-024-03839-7","article-title":"Integration of bulk and single-cell RNA-seq reveals prognostic gene signatures in patients with bladder cancer treated with immune checkpoint inhibitors","volume":"74","author":"Cho","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12672-024-01548-2","article-title":"Comprehensive analysis of single-cell and bulk RNA sequencing reveals postoperative progression markers for non-muscle invasive bladder cancer and predicts responses to immunotherapy","volume":"15","author":"Xiao","year":"2024","journal-title":"Discov Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12935-024-03447-6","article-title":"Identification of tumor-specific T cell signature predicting cancer immunotherapy response in bladder cancer by multi-omics analysis and experimental verification","volume":"24","author":"Liu","year":"2024","journal-title":"Cancer Cell Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1607222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:17:43Z","timestamp":1763619463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1607222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2025.1607222"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1607222","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1607222"}}